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Background-—It is uncertain how intracranial stenting (ICS) has been adopted nationally during a period characterized by a
restrictive payment policy by the Centers for Medicare & Medicaid Services, humanitarian device exemption approval by the Food
and Drug Administration, and insufﬁcient evidence of effectiveness. We sought to determine the trends in rates of ICS use and
associated outcomes in the United States.
Methods and Results-—From 65 211 328 Medicare Fee-for-Service beneﬁciaries hospitalized between 2006 and 2010 in acute
care hospitals in the United States, we included patients with ICD-9-CM procedure codes for intracranial angioplasty and stenting,
excluding those with a principal discharge diagnosis code of cerebral aneurysm or subarachnoid hemorrhage. We report operative
rates per 1 000 000 person-years and outcomes including 30-day and 1-year mortality rates. There were 838 ICS procedures
performed among Fee-for-Service beneﬁciaries. The overall hospitalization rate for ICS increased signiﬁcantly from 1 per
1 000 000 person-years (n=35 procedures) in 2006 to 9 per 1 000 000 person-years (n=258 procedures) in 2010 (P=0.0090 for
trend). Procedure rates were higher in men than in women, and were highest among patients aged 75 to 84 years and lowest
among those ≥85 years. The 30-day mortality rate increased from 2.9% (95% CI, 0.1 to 15.3) to 12.9% (95% CI, 9.0 to 17.6),
P=0.1294 for trend, and the 1-year mortality rate increased from 14.7% (95% CI, 5.0 to 31.1) to 19.5% (95% CI, 14.9 to 24.9),
P=0.0101; however, the annual changes were not signiﬁcant after adjustment.
Conclusions-—ICS utilization in the United States has modestly increased during a period of inadequate supportive evidence.
Humanitarian device exemption and a restrictive payment policy appear to have caused slow adoption of the technology. (JA m
Heart Assoc. 2013;2:e000084 doi: 10.1161/JAHA.113.000084)
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I
ntracranial atherosclerosis causes 8% to 10% of all
ischemic strokes in the United States
1,2 and is associated
with a high rate of recurrent stroke. Given the persistent risk
of recurrence despite optimal medical management strate-
gies,
3,4 there is strong interest in alternative treatment
options such as intracranial stenting (ICS). The Wingspan
stent, designed speciﬁcally for use in intracranial atheroscle-
rotic disease, was granted humanitarian device exemption
(HDE) approval by the United States Food and Drug Admin-
istration (FDA) in August 2005.
5 HDE waives the requirement
that a manufacturer submit a premarket approval application
to demonstrate a product’s effectiveness through scientiﬁ-
cally valid clinical investigations. The device was indicated for
“improving cerebral artery lumen diameter in patients with
≥50% stenosis, refractory to medical therapy that is acces-
sible to the system.”
5
The lack of evidence about the procedure engendered some
controversy. A joint position statement
6 by major radiology
and neuroradiology societies in October 2005, in alignment
with the FDA indication, concluded that balloon angioplasty
with or without stenting should be considered in a subgroup of
patients who had failed medical therapy. However, the studies
that were available included individual reports and case series
that were not designed to demonstrate the superiority of
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7–10 A Coch-
rane review in 2006
11 stated that the evidence precluded any
conclusions about the effectiveness of the procedure. The
same year, the Centers for Medicare & Medicaid Services
(CMS) provided coverage for this procedure only in the context
of a randomized trial.
12 In 2011, published results of the
Stenting and Aggressive Medical Management for Preventing
Recurrent stroke in Intracranial Stenosis (SAMMPRIS) trial
demonstrated that intracranial angioplasty and stenting more
than doubled the risk of stroke or death within 30 days
compared with medical management alone in patients who
had a recent stroke or transient ischemic attack.
13 This risk
remained elevated even at 1 year, with a mean follow-up
period of 11.9 months.
To determine the adoption pattern of this new technology,
we analyzed a 100% sample of Medicare Fee-for-Service
beneﬁciaries to determine national trends in ICS utilization
rates and outcomes among patients with intracranial athero-
sclerotic disease from 2006 to 2010, the period during which
there was no randomized trial evidence. We also sought to
study a subgroup of patients who met the eligibility criteria for
enrollment in SAMMPRIS to estimate the pattern of use in this
cohort since the approval of the technology.
Methods
Data Sources and Coding
We used data from Medicare inpatient standard analytical
ﬁles from CMS to identify all Fee-for-Service beneﬁciaries who
were hospitalized for intracranial angioplasty and stenting
between January 1, 2006, and December 31, 2010. We
deﬁned ICS using International Classiﬁcation of Diseases,
Ninth Revision, Clinical Modiﬁcation procedure codes for both
intracranial angioplasty (00.62) and ICS (00.65). We excluded
beneﬁciaries younger than 65 years and those with a
principal discharge diagnosis code of subarachnoid hemor-
rhage (430) or cerebral aneurysm (437.3).
For secondary analyses, we further deﬁned a subgroup of
patients who were most comparable to those meeting
eligibility criteria for enrollment in SAMMPRIS. From the
primary sample, we identiﬁed hospitalizations that had
principal discharge diagnosis codes for stroke (434.91) or
transient ischemic attack (435.0, 435.1, 435.3, 435.8, and
435.9) within 30 days of or during index admission. We
ascertained dates of death through the corresponding vital
status information in the denominator ﬁles.
Patient Characteristics and Comorbidities
We examined demographic characteristics of patients who
underwent ICS, including age, sex, and race. We determined
race using the Medicare denominator ﬁle, which uses
patient-reported data from the Social Security Administra-
tion.
14 We identiﬁed clinical comorbidities using secondary
diagnosis codes that did not represent potential complica-
tions (Appendix S1) from the initial ICS hospitalization as well
as principal and secondary diagnosis codes of all hospital-
izations for any cause in the 12 months before the initial ICS
hospitalization.
ICS Hospitalization Rates and Outcomes
For each year, we calculated the ICS hospitalization rate by
dividing the total number of ICS hospitalizations by the total
accumulated person-years. Because in a given year some
beneﬁciaries may be enrolled in Medicare Fee-for-Service for
<12 months, we calculated the total number of beneﬁciary-
months at risk and then converted to person-years for the
denominator.
To calculate in-hospital, 30-day, and 1-year mortality, we
identiﬁed all hospitalizations that occurred for ICS in a given
year. If a patient had multiple hospitalizations for ICS in a
given year, we selected 1 at random, consistent with methods
used to calculate CMS publicly reported mortality measures.
The procedure date of that hospitalization represented the
“time zero” for the mortality analysis. As a result, the 30-day
and 1-year mortality rates represented the likelihood of death
within 30 days and 1 year of the procedure among patients
hospitalized for ICS in a given calendar year. To generate 30-
day readmission rates, we restricted the sample to patients
who were discharged alive and not transferred to another
acute care hospital. The date of index discharge represented
“time zero” for readmission.
Statistical Analysis
We expressed the ICS hospitalization rate as per 1 000 000
person-years, mortality and readmission rates as percentages,
and length of stay as mean (standard deviation [SD]) days. We
used the Mantel–Haenszel chi-square test to analyze whether
changes over time in the outcomes were statistically signif-
icant. To assess the annual change in ICS hospitalization
rates, we ﬁtted a linear mixed-effects model with a Poisson
link function and state-speciﬁc random intercepts, adjusted
for demographics. For this analysis, we included a continuous
time variable, ranging from 0 to 4, corresponding to years
2006–2010, to estimate the risk-adjusted incidence rate ratio
(IRR) that represents the annual change in ICS hospitalizations
during that period. To obtain the annual change in mortality
rates adjusted for patient demographics and comorbidities,
we ﬁtted a linear mixed-effects model with a logit link function
and state-speciﬁc random intercepts. We used the time
variable, described previously, to calculate the risk-adjusted
DOI: 10.1161/JAHA.113.000084 Journal of the American Heart Association 2
Trends in Intracranial Stenting, 2006–2010 Gupta et al
O
R
I
G
I
N
A
L
R
E
S
E
A
R
C
Hodds ratio (OR) that represents the annual change in ICS
mortalities from 2006 to 2010.
For 30-day all-cause readmission rates, we conducted
survival analysis to calculate the proportion of patients who
were readmitted to any hospital within 30 days of discharge
for the index ICS procedure, censoring those who died before
readmission. We constructed a Cox proportional model with
state-speciﬁc random intercepts and the time variable to
evaluate the annual changes in 30-day all-cause readmission
rates over time adjusted for patient demographics and
comorbidities.
We conducted the analyses with SAS version 9.3 64-bit
(SAS Institute Inc, Cary, NC). The signiﬁcance level for all
analyses was P<0.05 using 2-sided tests. The Institutional
Review Board at Yale University approved the study.
Results
ICS Hospitalizations and Patient Characteristics
The ﬁnal sample included 146 459 811 observations in the
denominator ﬁles from 2006 to 2010, representing
65 211 328 individual Medicare beneﬁciaries who contrib-
uted a total of 139 067 831 person-years of observation.
There were 838 ICS procedures contributed by 826 individual
Medicare Fee-for-Service beneﬁciaries performed during the
study period (Table 1). The overall hospitalization rate for ICS
increased signiﬁcantly, from 1 per 1 000 000 person-years
(n=35 procedures) in 2006 to 9 per 1 000 000 person-years
(n=258 procedures) in 2010 (P=0.0090 for trend; Figure 1).
After controlling for age, sex, and race, the risk-adjusted IRR
that represents the relative annual change in the ICS
hospitalization rate was 1.72 (95% conﬁdence interval [CI],
1.69 to 1.76). Increases in ICS rates were observed across all
age, sex, and race subgroups (Table 1). The hospitalization
rate for ICS was higher in men than in women throughout the
study period, with 2010 rates of 12 per 1 000 000 and 7 per
1 000 000, respectively. In 2010, the ICS rate was observed
to be highest in patients aged 75 to 84 years (11 per
1 000 000), followed by those aged 65 to 74 years (10 per
1 000 000) and ≥85 years (5 per 1 000 000). The ICS
hospitalization rate was comparable among blacks and whites
across the study period, with a rate of 9 per 1 000 000 for
both in 2010.
Over time, the mean age, sex, and race of patients did not
vary substantially. Between 2006 and 2010, there was a
decrease in prevalence for some comorbidities, most notably
hypertension (85.3% to 75.0%; P=0.0776 for trend), diabetes
mellitus (41.2% to 27.7%; P=0.1953 for trend), and athero-
sclerotic disease (52.9% to 31.3%; P=0.0222, for trend).
Mortality Outcomes
The overall in-hospital mortality rates were 2.9% (95% CI, 0.1%
to 15.3%) and 9.0% (95% CI, 5.8% to 13.2%) in 2006 and 2010,
respectively (Table 2). The overall 30-day mortality rate for
ICS patients was 2.9% (95% CI, 0.1% to 15.3%) in 2006 and
12.9% (95% CI, 9.0% to 17.6%) in 2010 (Table 2). The annual
Table 1. ICS Hospitalization Rates of Medicare Fee-for-Service Beneﬁciaries, 2006–2010
2006 2007 2008 2009 2010
Person-years 28 452 501 27 899 732 27 675 586 27 343 436 27 696 576
ICS Hospitalizations (n) 35 101 216 228 258
Rate of ICS (per 1 000 000 person-years) 1 4 8 8 9
By age* (y)
65 to 74 1 3 7 8 10
75 to 84 2 4 9 10 11
≥8 5 02655
By sex*
Male 2 5 10 10 12
Female 1 3 7 7 7
By race*
White 1 4 8 8 9
Black 1 4 11 10 9
Other
† 12681 2
ICS indicates intracranial stenting.
*Rates within subgroups reported per 1 000 000 person-years.
†Includes Asian, Hispanic, North American Native, and other not speciﬁed.
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Hchange in 30-day mortality rate was not signiﬁcant after
adjustment for patient demographics and comorbidities (OR,
1.09; 95% CI, 0.87 to 1.36; Figure 2).
The 1-year mortality rate for ICS increased from 14.7%
(95% CI, 5.0% to 31.1%) in 2006 to 19.5% (95% CI, 14.9% to
24.9%) in 2010, but this increase was not signiﬁcant after
adjustment for patient demographics and comorbidities (OR,
1.05; 95% CI, 0.88 to 1.25; Figure 2). The rates were highest
for those aged 85 years and older (35.7% in 2010), followed
by the 75- to 84- and 65- to 74-year age groups (2010, 20.0%
and 15.8%, respectively). In 2010, women had higher 1-year
mortality than men (23.3% versus 16.4%). Nonetheless, 1-year
mortality rates increased across the subgroups of age, sex,
and race throughout the study period.
Readmission and Length of Stay
The 30-day readmission rate was 6.1% (95% CI, 0.7% to 20.2%)
in 2006, compared with 14.7% (95% CI, 10.4% to 19.9%) in
2010 (Table 2). The annual increase in the 30-day readmission
rate was not signiﬁcant after adjustment for patient demo-
graphics and comorbidities (OR, 1.12; 95% CI, 0.92 to 1.36;
Figure 2). Over time, mean (SD) hospital length of stay
increased from 3.6 (4.9) to 5.7 (8.3) days (P=0.1507 for
trend).
Subgroup Analyses
We identiﬁed 310 patients during 2006–2010 who met
eligibility criteria for enrollment in SAMMPRIS. The number of
ICS procedures performed in this subgroup increased from 6
in 2006 to 107 in 2010. The overall 30-day readmission rate
in this subgroup was 10.3%, 30-day mortality rate was 18.6%,
and 1-year mortality rate was 26.5%.
Among the 310 patients who met eligibility criteria for
SAMMPRIS, 202 were admitted with stroke and 108 with a
transient ischemic attack within 30 days preceding admis-
sion. The overall 30-day readmission rates were 9.9% in
patients with stroke and 11.1% in patients with transient
ischemic attack during 2006–2010. The 30-day mortality
Figure 1. Left y axis corresponds to the intracranial stenting (ICS) procedure rate. Right y axis corresponds to total ICS procedures and
cumulative ICS procedures.
Table 2. Outcomes Among Patients Undergoing ICS in Medicare Fee-for-Service, 2006–2010
2006 2007 2008 2009 2010
LOS in days, mean (SD) 3.6 (4.9) 4.6 (4.7) 4.8 (7.7) 3.8 (4.7) 5.7 (8.3)
30-day readmission, % 6.1 (0.7 to 20.2) 12.5 (6.4 to 21.3) 10.8 (6.8 to 16.0) 7.2 (4.1 to 11.6) 14.7 (10.4 to 19.9)
In-hospital mortality, % 2.9 (0.1 to 15.3) 8.3 (3.7 to 15.8) 7.5 (4.4 to 12.0) 7.9 (4.8 to 12.2) 9.0 (5.8 to 13.2)
30-day mortality, % 2.9 (0.1 to 15.3) 11.5 (5.9 to 19.6) 9.9 (6.2 to 14.7) 11.4 (7.6 to 16.3) 12.9 (9.0 to 17.6)
1-year mortality, % 14.7 (5.0 to 31.1) 14.6 (8.2 to 23.3) 17.5 (12.6 to 23.2) 18.4 (13.6 to 24.1) 19.5 (14.9 to 24.9)
ICS indicates intracranial stenting; LOS, length of stay; SD, standard deviation.
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Hrates were 17.3% and 21.3% and the 1-year mortality rates
were 25.7% and 27.8% among patients with stroke and
transient ischemic attack, respectively.
Discussion
During a period of uncertainty about the efﬁcacy and safety of
intracranial angioplasty and stenting, CMS imposed a highly
restrictive payment policy that limited reimbursement to
patients who were enrolled in a randomized trial.
12 We found
limited adoption of the technology from 2006 to 2010,
although during that time there were 826 Medicare Fee-for-
Service beneﬁciaries who received ICS. This group may have
included some patients from SAMMPRIS, but the number is
likely to have been small given that there were only 224
patients, with an average age of 61.0 years, recruited into the
ICS arm of SAMMPRIS.
13
Under an HDE application for patients who are refractory
to medical therapy, the Wingspan Stent System was approved
by the FDA in 2005 on the basis of a single, uncontrolled, 45-
subject trial that was not designed to demonstrate whether
utilization of the device was safer or more effective than
medical therapy alone.
15,16 Most of the studies conducted
before and after the Wingspan device was approved either
had no control group that received medical therapy
alone
15,17–22 or involved comparison with a historical
9,23 or
a nonrandomized
24 control group. Thus, valid conclusions
could not be drawn regarding the relative safety or efﬁcacy of
stenting over standard medical therapy alone. During a time
of uncertainty surrounding rational utilization of ICS in
patients with intracranial atherosclerotic disease and lack of
an evidence base demonstrating its efﬁcacy over medical
therapy, our study demonstrates a small absolute increase in
adoption of the procedure over recent years.
SAMMPRIS, the only published clinical trial of this tech-
nology, was published 6 years after the stent was approved.
13
Recruitment was prematurely discontinued after the ﬁnding
that the 30-day rate of stroke or death in patients randomized
to the ICS arm was nearly 2.5 times that of patients who
received aggressive medical management alone. Notably,
although the inclusion of patients in SAMMPRIS did not
require refractoriness to medical therapy, about two thirds of
the patients were on antithrombotic therapy at the time of
randomization. In addition, many patients who would not have
qualiﬁed for the SAMMPRIS trial also received this procedure.
Because of lack of clinical data, it is not possible to ascertain
whether they were symptomatic. However, criteria for
recruitment in SAMMPRIS were not in alignment with the
FDA indication for ICS, and that may partly account for this
observation. As per the FDA indication for ICS, refractory
medical therapy was not clearly deﬁned, whereas SAMMPRIS
recruited patients within 30 days of stroke or transient
ischemic attack.
CMS may be credited for the regulated adoption of this
technology that lacked sufﬁcient evidence for its use. After its
decision in 2006 to offer coverage for ICS only when it is
furnished in accordance with FDA-approved protocols gov-
erning investigation device-exemption clinical trials, CMS
maintained this judgment despite a petition for broader
coverage ﬁled in 2008 by Boston Scientiﬁc.
25 In comparison,
endovascular devices for mechanical embolectomy in acute
stroke patients were approved through the FDA’s 510(k)
Figure 2. Adjusted odds ratios for annual change in outcomes in patients receiving intracranial stenting among Medicare Fee-for-Service
beneﬁciaries during 2006–2010.
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Hpathway and are fully reimbursed by CMS, leading to a much
more rapid rate of increase in their use in recent years.
26
These instances demonstrate how regulatory bodies like CMS
and the FDA can act as gatekeepers for the diffusion of a
technology into clinical practice that may have considerable
implications on the quality and cost of health care.
27
Our database did not allow comparison with patients who
received medical management alone, restricting any conclu-
sion regarding safety or efﬁcacy of this procedure. Notably,
the 30-day mortality rate that we observed among recipients
of ICS in 2010 was 12.9%, much higher than the rates
reported by previous observational prospective and registry
studies (0% to 6%).
28 Our study included only patients who
were aged ≥65 years, unlike previous work that included
younger patients. This could partly account for the discor-
dance in outcomes. It is also possible that the outcomes of
intracranial stenting are worse in practice than previously
documented.
In light of results from SAMMPRIS, Public Citizen, a
consumer watchdog group, petitioned the FDA in December
2011 to withdraw approval of the Wingspan Stent Sys-
tem.
29,30 In response, representatives of Boston Scientiﬁc
argued that SAMMPRIS was not designed to evaluate the
safety of the stent in patients who are refractory to medical
therapy, and thus this should not affect FDA approval for HDE-
indicated patients. Most recently, in August 2012, the FDA
denied the petition, stating that it has taken regulatory
actions to better deﬁne the indications and intended popu-
lation for the use of the Wingspan stent, now marketed by
Stryker Corp.
30
Our study has several limitations. The analyses were
limited to Medicare Fee-for-Service beneﬁciaries, which
restricted the generalization of our results to patients younger
than 65 years. However, 70% of ischemic strokes occur in
patients who are older than 65 years,
31 which supports the
relevance of our focus on this subgroup. In addition, we
cannot comment on trends in patients enrolled in Medicare
managed care programs. As more patients have migrated into
Medicare managed care programs over time,
32 related
changes in the Fee-for-Service population may have affected
the observed trends. In addition, we could not distinguish the
procedure rates and outcomes of patients who received ICS
urgently from those of patients who underwent this procedure
in an elective setting. Such information cannot be reliably
obtained from the Medicare database. Also, we may have
captured patients who received ICS for other indications.
However, we excluded patients who had primary diagnoses of
cerebral aneurysm and subarachnoid hemorrhage, the other 2
common indications of ICS. It is also possible that miscoding
caused some basilar and vertebral artery procedures to be
missed. However, coding guidelines issued by CMS require
all intracranial procedures to be assigned codes for intracra-
nial angioplasty and stenting. In addition, our study period
ranged from 2006 to 2010, following the introduction of
the codes for intracranial stenting and coding guidelines.
Finally, we relied on administrative claims data to obtain
comorbidities.
Summary
The rate of ICS utilization in the United States modestly
increased during 2006–2010, but over this period <1000
patientsolderthan65 yearsofageweretreated. Theapproach
of HDE and a restrictive payment policy appear to have caused
slow adoption of the technology in the treatment of Medicare
beneﬁciaries. Unfortunately, 8 years after approval, uncer-
tainty remains regarding the safety and effectiveness of the
device in patients who are refractory to medical therapy, even
as the harm demonstrated by SAMMPRIS has justiﬁed the
cautious approach taken by regulatory agencies.
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